A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
← catalyst calendarNCT06679946 · readout in 590 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
700estimated
Sites
87
Countries
Argentina, Austria, Belgium +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-03 | actual | When the study began enrolling |
| Primary completion | 2028-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intervention
- Drug: Vutrisiran — also filed as ALN-TTRSC02, AMVUTTRA®
Primary outcome
what the primary-completion date above is the date OFFrequency of Adverse Events (AEs)
measured Up to 36 Months
Publications
- PMID 39213194 — reports results
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed